Lactoferricin vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Lactoferricin
Lactoferricin is an antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. It has potent antibacterial, antiviral, and antifungal properties.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | Lactoferricin | Cagrilintide |
|---|---|---|
| Mechanism | Binds to and disrupts microbial membranes through electrostatic interactions. Also binds to lipopolysaccharide (LPS) to neutralize endotoxins and has immunomodulatory effects. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Research applications vary widely. Oral lactoferrin supplements (containing lactoferricin precursor) typically dosed at 100-400mg daily. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Available through lactoferrin supplementation orally. Purified lactoferricin primarily used in research settings. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Lactoferrin supplementation is generally well-tolerated. May cause GI upset in some individuals. Derived from milk so caution with dairy allergies. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |